{"id":1022013,"date":"2026-11-17T18:38:06","date_gmt":"2026-11-17T23:38:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/"},"modified":"2026-11-17T18:38:06","modified_gmt":"2026-11-17T23:38:06","slug":"sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/","title":{"rendered":"SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Nov.  17, 2026  (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (\u201cSELLAS\u201d or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. SELLAS intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock under the same terms and conditions. All of the shares in the offering will be sold by SELLAS. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.<\/p>\n<p align=\"justify\">J.P. Morgan and TD Cowen are acting as the joint book-running managers for the offering.<\/p>\n<p align=\"justify\">The public offering will be made pursuant to a shelf registration statement on Form S-3 (File\u00a0No. 333-294504) that was previously filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on March 20, 2026, and became automatically effective upon filing. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC\u2019s website located at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oXExX55zXZ5awTlEzNhbPc54xrMqSStAE8kESfr1IEistiO3IYWBfvEjlFO_eJyEqlCTORXNXCjHrAtt61YhKA==\" rel=\"nofollow\" target=\"_blank\"><strong><u>http:\/\/www.sec.gov<\/u><\/strong><\/a><strong>. <\/strong>The offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained, when available, from J.P. Morgan Securities LLC, c\/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmorganchase.com and postsalemanualrequests@broadridge.com; or TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com<strong>.<\/strong><\/p>\n<p align=\"justify\">This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.<\/p>\n<p align=\"justify\">\n        <strong>About SELLAS Life Sciences Group, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS\u2019 lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib), a small molecule CDK9 inhibitor, for the treatment of AML in patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements. All statements other than statements of historical facts are \u201cforward-looking statements,\u201d including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as \u201cplan,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cproject,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cintend,\u201d or \u201ccontinue\u201d and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS and SLS009 clinical development programs, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties, including the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering, as well as risks and uncertainties inherent in SELLAS\u2019 business, including those described in the company\u2019s periodic filings with the SEC. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption \u201cRisk Factors\u201d in SELLAS\u2019 Annual Report on Form 10-K filed on March 19, 2026 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS\u2019 forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.<\/p>\n<p>\n        <strong>Investor Contact <\/strong>\n      <\/p>\n<p>John Fraunces<br \/>Managing Director<br \/>LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KWLSiwBljS1uTcBfPxysvpVLH7dd6q0UyKQNiYHRQVq9ZxJdK6AcoChtTGGwTRjLroyLMF3YJ569GYi7Fid_FbZZZnTlgGK6UEsZ6RYSpjekMXsYygZcjP45N_6bZ7FVqN97idsl4Z3J53ag0I2y333gKKoCKhWXSfmFGARFE4Mewo-sNojHxmJQ7VadXiOWfbjYN5vEECb_2v67q2aCArVO6raltXC8WzUwfahOOs_dftgTsBLxqCkO0WqrD7TTuDxNKyG_lsMF2fLttP48tCBSBbu8B0lsyWB6HuOqDDMZWBSSfJU3QA6XGflfGdcA\" rel=\"nofollow\" target=\"_blank\">jfraunces@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong>\n      <\/p>\n<p>Joan Bosisio<br \/>VP, Scientific &amp; Medical Communications<br \/>Simpson Healthcare<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xcnle28WcK4O_M5mY5T-ONLJlatUDCHFpkK_L3OSukgyxXrW01bADAzXsytTwUTkM87cr2Fy_dBIvjWk6V1eKoMI5jgCuYOrEpOSFmrQXUzYLy_ovajzoIAwKg-5-9VET1GmlRr_CDMtNzVupJ8FZVHCgxAGPF7bJWLcTI0szf4j5232ogPz1qejF0oXxpJ7Rk2HcUV5szoyBJObJhFhgywDJe8NDpR4TP9QQQpgFjhmtvIHyJ0G909Fe3GntUKRtgn4WNYFYkpTPw32JPk7GkGtpv2Z8-jc0U654mKavibIRsnkUlfPVWdXalnjJgmp\" rel=\"nofollow\" target=\"_blank\">jbosisio@simpsonhealthcare.com<\/a><\/p>\n<p align=\"justify\">Source: SELLAS Life Sciences Group, Inc.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTg0MCM3OTcyMTY1IzIxMjQzMjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDk1MjhkM2MtMzgwOC00NDUxLTk3NzUtNjhiYTZlYWQ0ZTIwLTExMzU4OTMtMjAyNi0xMS0xNy1lbg==\/tiny\/SELLAS-Life-Sciences-Group-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (\u201cSELLAS\u201d or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. SELLAS intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock under the same terms and conditions. All of the shares in the offering will be sold by SELLAS. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1022013","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (\u201cSELLAS\u201d or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. SELLAS intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock under the same terms and conditions. All of the shares in the offering will be sold by SELLAS. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering &hellip; Continue reading &quot;SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-17T23:38:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTg0MCM3OTcyMTY1IzIxMjQzMjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering\",\"datePublished\":\"2026-11-17T23:38:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\\\/\"},\"wordCount\":820,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTg0MCM3OTcyMTY1IzIxMjQzMjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\\\/\",\"name\":\"SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTg0MCM3OTcyMTY1IzIxMjQzMjI=\",\"datePublished\":\"2026-11-17T23:38:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTg0MCM3OTcyMTY1IzIxMjQzMjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTg0MCM3OTcyMTY1IzIxMjQzMjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/","og_locale":"en_US","og_type":"article","og_title":"SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering - Market Newsdesk","og_description":"NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (\u201cSELLAS\u201d or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. SELLAS intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock under the same terms and conditions. All of the shares in the offering will be sold by SELLAS. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering &hellip; Continue reading \"SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-17T23:38:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTg0MCM3OTcyMTY1IzIxMjQzMjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering","datePublished":"2026-11-17T23:38:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/"},"wordCount":820,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTg0MCM3OTcyMTY1IzIxMjQzMjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/","name":"SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTg0MCM3OTcyMTY1IzIxMjQzMjI=","datePublished":"2026-11-17T23:38:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTg0MCM3OTcyMTY1IzIxMjQzMjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTg0MCM3OTcyMTY1IzIxMjQzMjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1022013"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022013\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1022013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1022013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1022013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}